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ABSTRACT: There is considerable evidence to support the
hypothesis that the blockade of nAChR is responsible for the
antidepressant action of nicotinic ligands. The nicotinic
acetylcholine receptor (nAChR) antagonist, mecamylamine,
has been shown to be an effective add-on in patients that do
not respond to selective serotonin reuptake inhibitors. This
suggests that nAChR ligands may address an unmet clinical
need by providing relief from depressive symptoms in
refractory patients. In this study, a new series of nAChR
ligands based on an isoxazole-ether scaffold have been
designed and synthesized for binding and functional assays. Preliminary structure−activity relationship (SAR) efforts identified
a lead compound 43, which possesses potent antidepressant-like activity (1 mg/kg, IP; 5 mg/kg, PO) in the classical mouse
forced swim test. Early stage absorption, distribution, metabolism, excretion, and toxicity (ADME-Tox) studies also suggested
favorable drug-like properties, and broad screening toward other common neurotransmitter receptors indicated that compound
43 is highly selective for nAChRs over the other 45 neurotransmitter receptors and transporters tested.
■ INTRODUCTION
Neuronal nicotinic acetylcholine receptors (nAChRs) are
pentamers assembled from varying combinations of subunits
(α2−α10, β2−β4) and belong to the ligand-gated ion channel
superfamily of neurotransmitter receptors.1−3 These receptors
are broadly distributed in the central and peripheral nervous
systems, where they modulate many processes, such as
ganglionic transmission regulated by α3β4*-nAChRs (the *
indicates that subunits other than those specified are known or
possible partners in the closed assembly), neuroprotection of
dopaminergic pathways and nociception mediated by α4*-
nAChRs, as well as learning, memory, and addiction by β2*-
nAChR.3−6 Over the past two decades, many compounds
targeting nAChRs have been tested in various stages of clinical
trials.7 However, only one new chemical entity, varenicline (1),
has been launched and marketed as a potent partial agonist at
the α4β2-nAChR for smoking cessation (Figure 1).8−10
Given nAChR subtype diversity and their involvement in the
modulation of a host of neurotransmitter systems, nicotinic
ligands have the potential to treat a multitude of central
nervous system (CNS)-related dysfunctions, including chronic
depression.8,11 There is considerable evidence to support the
hypothesis that the blockade (antagonism or receptor
desensitization) of nAChR is responsible for the antidepressant
action of nicotinic ligands.12−14 In particular, clinical studies
have shown that the cholinesterase inhibitor, physostigmine,
produces depressive symptoms in humans,15 whereas mecamyl-
amine16 and the muscarinic antagonist scopolamine17,18 relieve
depressive symptoms in humans. Additionally, preclinical
studies provide support for the hypothesis that increased
cholinergic activity leads to depressed mood states. Flinders
sensitive rats, a line selectively bred for increased cholinergic
sensitivity, exhibit several depressive-like behaviors.19,20 More-
over, administration of the nicotinic antagonist mecamylamine
elicits an antidepressant-like effect in the mouse forced swim
test, and this effect is reduced when the β2 subunit gene is
knocked out.11 The same effects were also observed in response
to the tricyclic antidepressant amitriptyline, strongly suggesting
that β2*-nAChRs are involved in the antidepressant efficacy of
nicotinic ligands.21 The α4β2-nAChR is the predominant
subtype in the vertebrate CNS, and the α4β2 nicotinic agonists
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cytisine (2),22 A-85380 (9),23 and compound 124 induce
antidepressant-like effects in mice that are similar to the effects
of the antagonist mecamylamine. The S-enantiomer of
mecamylamine (TC-5214, 5) is an α4β2-nAChR modulator
now in Phase II clinical trials for use in the treatment of
depression.25 Therefore, the α4β2-nAChR is an attractive target
for the development of novel antidepressants, although it is
unclear whether nAChR activation, desensitization, or some
combination of both is essential. It is also known from clinical
studies that α3β4*-nAChRs contribute to adverse side effects in
vivo, although roles in mood control also are possible, as
exemplified by mecamylamine.26−28 Consequently, we chose to
focus on developing potent agonists selective for the α4β2-
nAChR, bearing in mind that activity at the α3β4*-nAChR
subtype might be an attribute or a detriment.
Multiple modifications to the structure of natural nicotinic
ligands, especially nicotine (3), epibatidine (4), and compound
2, have already been explored over the past 20 years. Most of
the reported nicotinic ligands bear a substituted pyridine ring as
the core scaffold. Some compound classes involving replace-
ment of the pyridine ring by isosteres have been investigated, as
exemplified by substituted phenyl derivatives,29 quinolines,30
furopyridines,31 structurally related chroman derivatives,32 and
most interestingly the five-membered heteroaromatic rings
isoxazole and isothiazole.33−37 The ability to replace the
pyridine moiety of S-(−)-nicotine with an isoxazole ring was
first investigated by Abbott Laboratories, leading to the clinical
study of ABT-418 (6) for the treatment of both Alzheimer’s
disease (AD) and attention deficit hyperactivity disorder
(ADHD). Compound 6 is a selective, full agonist at the
α4β2-nAChR with a Ki value of 7.4 nM.
8,38 The complete
subtype selectivity profile was not determined. In preclinical
studies, compound 6 demonstrated efficacy and potency similar
to that of compound 3 in animal models of cognition while
exhibiting reduced toxicity.38 Although compound 6 failed in
clinical development due to the occurrence of nausea as a side
effect, isoxazole-containing nicotinic ligands remain an exciting
area of investigation. Substituted isoxazoles were also
successfully applied in optimization studies of compound 4.
Replacement of the chloropyridyl group in compound 4 with a
methylisoxazolyl group led to epiboxidine (7),39,40 which was
approximately 10-fold less potent than compound 4 but 17-fold
more potent than compound 6 in the displacement of
[3H]nicotine at the α4β2-nAChR from rat cerebral cortical
membranes. Epiboxidine retained analgesic activity in mice at
25 mg/kg compared to compound 4 at 10 mg/kg, with greatly
reduced toxicity. Furthermore, a series of 3-(5-isoxazolyl)-
methylene-1-azabicyclic compounds (8) were synthesized as
potent nicotinic ligands.41
Pyridyl ethers, in which a CH2O linker is inserted between
compound 3’s pyrrolidine (or in analogues, azetidine) ring and
its pyridine ring, have attracted considerable interest as α4β2-
nAChR agonists because of their high potency.42,43 For
example, compound 9 possesses a Ki value of ca. 50 pM and
a high efficacy of 163% compared to compound 3 at the human
α4β2-nAChR.44 ABT-594 (10), a nAChR agonist, was
advanced to a Phase II clinical trial for the treatment of
chronic and neuropathic pain with a potency 50 times that of
morphine but was discontinued due to an unacceptably narrow
therapeutic index.45,46 ABT-089 (11) is currently under
investigation as a replacement for compound 6 that has an
improved preclinical therapeutic index and a better pharmaco-
kinetic profile. It has gone through Phase II clinical studies for
cognitive dysfunction.47,48 Upon the basis of the precedent
quoted above, we anticipated that an isoxazole moiety could be
used as a readily accessible replacement for the pyridine core in
the design of new nicotinic ligands. Herein, we report the
synthesis and pharmacological evaluation of a novel series of
nAChR ligands based on an isoxazole core in combination with
the CH2O linker (“isoxazole ethers”; Figure 2). Selected
compounds were further assessed in behavioral tests, in a broad
screening panel of common CNS neurotransmitter receptors
and transporters, as well as in preliminary in vitro ADME-Tox
studies.
■ RESULTS AND DISCUSSION
Chemistry. First, we designed compounds that could be
accessed from readily available starting materials to ascertain
whether an isoxazole moiety could replace the pyridine core in
the previously published pyridine ether nicotinics developed by
Abbott. The 3-alkoxyisoxazoles 18−21 were synthesized in 3−6
steps utilizing the synthetic routes shown in Scheme 1.
Intermediate 16 was formed via the Mitsunobu reaction of
Boc-protected 2(S)-azetidinylmethanol (15) and 3-hydroxyi-
soxazole-5-carboxylic acid methyl ester (14), which was in turn
prepared as described in the literature from dimethyl 2-
butynedioate (13). The ester 16 was subsequently reduced with
LiBH4 to furnish the primary alcohol 17, and this intermediate
was carried on to the iodide. The phenyl ether 19 and the
aliphatic ethers 20−21 were obtained through nucleophilic
Figure 1. Selected nicotinic acetylcholine receptor ligands.
Figure 2. General structure of the present series of isoxazole ether
nAChR ligands.
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substitution following standard methods. After acidic depro-
tection and subsequent purification by HPLC, compounds 18−
21 were obtained as trifluoro acetates. The number of
equivalents of trifluoroacetic acid (TFA) in these non-
stoichiometric compounds was determined by elemental
analysis. The 5-methylated 3-alkoxyisoxazole 24 was synthe-
sized in the same manner from commercially available 3-
hydroxy-5-methylisoxazole 22 (Scheme 1).
The preparation of 5-alkoxyisoxazole ligands proceeded
through the common intermediates 29 and 30, which were in
turn prepared from the commercially available ester 26
(Scheme 2). Compounds 31, 32, 33, and 43 were synthesized
by employing the same strategy as described in Scheme 1. The
primary alcohol 29 was transformed to an iodide, followed by
nucleophilic substitution with aniline or 4-fluoroaniline to
afford the precursors of amine derivatives 34 and 35.
Carbamate analogues 34−38 were prepared by reaction of 29
with the corresponding isocyanates. The fluoromethyl deriva-
tive 39 was obtained by treatment of alcohol 29 with
(diethylamino)sulfur trifluoride. Subsequent Boc deprotection
of the precursors yielded the desired final compounds 34−39.
In Vitro Characterization−Radioligand Binding Stud-
ies. In vitro binding affinities of the five 3-alkoxyisoxazoles
(18−21, 24) were determined by the standard [3H]epibatidine
binding assay at seven rat nAChR subtypes (Table 1).49 While
this initial set of compounds showed weak binding to all seven
nAChR subtypes tested, compound 18 exhibited a moderate
affinity for α4β2- and α4β2*-nAChRs.
Scheme 1a
aReagents and conditions: (a) N-hydroxyurea, 1,5-diazabicyclo[5.4.0]undec-5-ene, MeOH, 0 °C, then HCl; (b) 1-(tert-butoxycarbonyl)-2(S)-
azetidinylmethanol (15), diisopropyl azodicarboxylate, PPh3, THF, 0 °C to rt; (c) LiBH4, THF, 0 °C to rt; (d) TFA, CH2Cl2; (e) I2, PPh3, imidazole,
CH2Cl2, 0 °C to rt; (f) phenol, K2CO3, DMF, rt; (g) NaH, DMF, RBr, 0 °C to rt.
Scheme 2a
aReagents and conditions: (a) diisopropyl azodicarboxylate, PPh3, THF, 0 °C to rt; (b) LiBH4, THF, 0 °C to rt; (c) TFA, CH2Cl2; (d) I2, PPh3,
imidazole, CH2Cl2, 0 °C to rt; (e) K2CO3, DMF, phenol, rt; (f) HNR
1R2, CH3CN, rt; (g) RN=CO, 4-(dimethylamino)pyridine, PhMe, 80 °C;
(h) Et2NSF3, CH2Cl2, −78 °C.
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It is commonly accepted that the essential pharmacophore of
nicotinic ligands consists of a cationic center (e.g., quaternized
or protonated nitrogen) and a hydrogen-bond acceptor (e.g., a
nitrogen atom in the case of pyridine-containing ligands).50
The inactivity of our first batch of isoxazole-ether compounds is
possibly a result of misalignment of these two key elements.
Therefore, to align these pharmacophoric elements differently,
and hopefully more appropriately, isoxazoles with a reverse
position of their N and O ring atoms were synthesized. As the
alcohol 18 (Table 1) was the only congener that so far showed
moderate affinity to the α4β2-nAChR, the reverse 5-
hydroxyisoxazole 31 (Table 2) and its phenyl ether 32 were
synthesized. Encouragingly, the binding affinities of 32 were
dramatically improved, while compound 31 maintained its
affinity in comparison to 18. Subsequently amines, carbamates,
simple alkyl, and fluoromethyl derivatives were synthesized to
further study the structure−activity relationship (SAR).
In general, most of the 5-alkoxyisoxazoles (Table 2) bind to
α4β2-nAChRs with nanomolar affinity. The binding affinities of
all amines (34, 35), carbamates (36, 37, and 38), the 3-methyl
derivative 43, and the 3-fluoromethyl derivative 39 were
increased 1.8−30-fold compared to the parent alcohol 31.
Compound 43 carrying a 3-methyl substituent turned out to
have the best affinity for α4β2- and α4β2*-nAChRs with Ki
values of 4.6 nM and 12.0 nM, respectively. All of these
compounds have a similar subtype selectivity profile as
compound 3 and compound 1;51 they display selectivity for
the α4β2- over the α3β4-nAChR in radioligand binding
competition assays. The alcohol 31, methyl derivative 43,
fluoromethyl derivative 39, and carbamates 36−38 actually
exceed compound 3’s α4β2- over α3β4- selectivity. Among
these ligands, the cyclopentylcarbamate 38 exhibits the best
selectivity with a Ki value of 13.1 nM at the α4β2-nAChR and
inactivity at the α3β4-nAChR. The aforementioned six
compounds also exhibit selectivity for all the other β2- over
β4-containing subtypes. Their affinities at the α4β2*-nAChR
dropped 1.6−13.5- fold compared to those at the α4β2-nAChR,
probably due to the existence of additional subunits in the
former.
To determine the influence of different heteroalicyclic ring
sizes, the pyrrolidine analogues 33 and 44 were also
synthesized. Pyrrolidines 33 and 44 retained all of the
selectivity exhibited by the corresponding azetidines (32 and
43), but their affinities were reduced at all seven rat nAChR
subtypes, which is consistent with previous studies in the
pyridine ether series.42
Table 1. Binding Affinities of 3-Alkoxyisoxazole Ligands at Seven Rat nAChR Subtypes
Ki (nM)
a
ID X α2β2 α2β4 α3β2 α3β4 α4β2 α4β2*b α4β4
18 OH 337 >104 990 >104 176 405 7530
19 OC6H5 NA
d NA NA NA NA NA NA
20 OCH3 NA NA 4100 NA NA NA NA
21 OCH2CH(CH2)2 NA NA NA NA NA NA NA
24 H 3340 >104 6670 >104 1950 7380 >104
3c 5.5 70.0 29.0 260 4.9 9.8 23.0
aSee Experimental Section. bα4β2*, endogenous receptors prepared from rat forebrain. Besides α4 and β2, other unidentified subunits may also be
present. Details are provided in the Experimental Section. cThe Ki values for compound 3 are taken from the PDSP Assay Protocol Book.
dNot
active, defined as <50% binding in the primary assay at 10 μM.
Table 2. Binding Affinities of 5-Alkoxyisoxazole Ligands at Seven Rat nAChR Subtypes
Ki (nM)
a
ID n X α2β2 α2β4 α3β2 α3β4 α4β2 α4β2*b α4β4 α7 α7*b
31 1 OH 197 >104 521 >104 137 637 4900 NDd ND
32 1 OC6H5 47.9 58.0 362 186 23.8 172 27.5 ND ND
33 2 OC6H5 176 320 2040 809 160 2120 55.1 ND ND
34 1 NHC6H5 150 144 462 771 75.9 386 33.2 ND ND
35 1 NHC6H4F-p 201 30.3 ND 171 49.0 417 9.9 ND ND
36 1 OC(O)NHC6H5 42.3 162 123 1760 19.7 157 60.0 ND ND
37 1 OC(O)NHC2H5 157 6570 315 NA
e 31.2 207 1240 ND ND
38 1 OC(O)NH-c-C5H11 126 9970 370 NA 13.1 149 3480 ND ND
39 1 F 11.8 472 17.3 1270 7.3 11.9 163 ND ND
43 1 H 4.3 311 8.7 692 4.6 12.0 86.0 2890 6790
44 2 H 616 5810 1030 8780 129 1100 4140 ND ND
3c 5.5 70.0 29.0 260 4.9 9.8 23.0 ND ND
1f 86 0.4 110 125
aSee Experimental Section. bα4β2* or α7*, endogenous receptors prepared from rat forebrain. Besides α4, β2, or α7, other unidentified subunits
may also be present. Details are provided in the Experimental Section. cThe Ki values for compound 3 are taken from the PDSP Assay Protocol
Book. dND: not detected. eNot active, defined as <50% binding in the primary assay at 10 μM. fThe Ki values for compound 1 are from ref 51.
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In Vitro Functional Characterization. The most potent
α4β2-nAChR ligands based on binding assays, 39 and 43, as
well as pyrrolidine analogue 44 were selected for evaluation of
functional activity using the 86Rb+ ion flux assay in SH-EP1-
hα4β2, SH-SY5Y (α3β4*) and TE671/RD (α1β1γδ) cells
(Figure 3; Tables 3 and 4). Consistent with the binding data,
the azetidines 39 and 43 were found to be more potent than
the pyrrolidine 44, both in agonism and functional inactivation
at the α4β2-nAChR (Figure 3, Table 3). Compounds 39 and
43 had agonist efficacies at the α4β2-nAChR comparable to
compound 3 and higher than that of compound 1. Compounds
39 and 43 have functional inactivation efficacies lower than
those of compound 3 or compound 1. They were both full
agonists at the α3β4*-nAChR, with potencies similar to those
seen at the α4β2-nAChR, though they were less potent in the
functional inactivation of the α3β4*-nAChR (Table 4, Figure
3). Whereas compounds 39 and 43 have high selectivity for
α4β2- over α3β4*-nAChRs (174- and 150-fold) in the binding
affinity assays (Table 2), this selectivity does not translate to
the functional assay (Tables 3 and 4, Figure 3). None of the
compounds displayed significant activity at the α1β1γδ-nAChR.
Compounds 31−38 were not potent in our preliminary
functional screening.
In addition, compounds 39 and 43 are similar in potency at
the α4β2-nAChR (EC50 values of 1090 nM and 1180 nM,
respectively) compared to compound 1 (EC50 value of 1400
nM). Both are inactive at the α1β1γδ-nAChR and have activity
similar to compound 1 at the α3β4*-nAChR. Whereas in vitro
binding and functional data are intriguing, a more proximal
measure of therapeutic value is likely to be behavioral
pharmacological activity in an animal model of the indication
of interest. Therefore, we decided to further test these
compounds for their antidepressant profile in vivo.
In Vivo Behavioral Studies−Mouse Forced Swim Test.
Antidepressant efficacy was assessed with the mouse forced
swim test, an assay in which a mouse is placed into a beaker of
water, and the time it spends passively floating in the water
(immobility) is recorded (Figure 4). Most traditional
antidepressants decrease the amount of time the mouse spends
immobile. Mice were administered compounds 43 (1 and 5
mg/kg ip) or the selective serotonin reuptake inhibitor (SSRI)
antidepressant, sertraline, as a positive control (10 mg/kg).
Drug administration produced a reduction in immobility.
Fisher’s post hoc tests showed that compound 43 reduced
immobility at both doses (1 and 5 mg/kg), suggestive of a
Figure 3. Functional activities of compounds 39, 43, and 44 at nAChR subtypes. Specific 86Rb+ efflux (ordinate; percentage of control ± SEM) was
determined as described in the Experimental Section for intrinsic agonist activity over a 9.5 min period for compounds 39 (left), 43 (middle), or 44
(right) at the indicated concentrations (abscissa; log molar scale) on human α4β2-nAChR (●), α3β4*-nAChR (▲), or α1β1γδ-nAChR (⧫)
naturally or heterologously expressed by SH-EP1-hα4β2, SH-SY5Y, or TE671/RD cells, respectively. Also shown are functional inactivation effects
of pretreatment for 10 min with the same agents at the indicated concentrations on subsequent agonist action of an EC90 concentration of the full
agonist, carbamylcholine (applied in the continuing presence of the indicated agents), acting at α4β2-nAChR (○), α3β4*-nAChR (Δ), or α1β1γδ-
nAChR (◇). Results are normalized to responses to a fully efficacious concentration of carbamylcholine (see Experimental Section for details).
Nanomolar agonist EC50 values and inactivation IC50 values are provided in Tables 3 and 4, as are agonism and inactivation efficacies (normalized to
those for a full agonist or antagonist, respectively). SEM values were determined for each parameter and although not presented here, typically are
less than 15% for efficacy measures and no more than a factor of 2 for molar EC50 or IC50 values. Compounds 39 and 43 have full agonist activity at
α4β2-nAChRs and α3β4*-nAChRs (efficacies are similar to that of carbamylcholine) and little activity at α1*-nAChRs. Compound 44 was less
potent than 39 and 43 by approximately 1 order of magnitude, so a full functional profile would have required 1 mM concentrations of the
compound and was not pursued.
Table 3. Potencies and Efficacies of Ligand Agonism and
Inactivation of Human α4β2-nAChRsa
agonism inactivation Ki (nM)
compound EC50 (nM) efficacy (%) IC50 (nM) efficacy (%) α4β2
39 1090 93 151 72 7.3
43 1180 108 169 78 4.6
44 >3000 >50 1100 69 129
3 290 88 430 92 4.9
1 1400 53 ∼110 ∼85 0.05
aSee Experimental Section for details. The term “inactivation” is used
because compounds may be acting to desensitize receptors or as
competitive or noncompetitive antagonists, and further work is needed
to make such a distinction. SEM values were determined for each
parameter and, although not presented here, typically are less than 3%
and frequently less than 1% of the maximal carbamylcholine response
for efficacy measures for ligands potent enough to reach maximal
efficacy at 10 μM. SEM values for EC50 and IC50 values were no more
than a factor of 2. See Table 2 for structures. For compounds that were
not potent enough to cause maximal inhibition at the highest
concentration tested, inactivation efficacy was fixed at 100% to allow
IC50 values to be fit during graphical analysis.
Table 4. Potencies and Efficacies of Ligand Agonism and
Inactivation of α3β4*-nAChRsa
agonism inactivation Ki (nM)
compound EC50 (nM) efficacy (%) IC50 (nM) efficacy (%) α3β4
39 3400 120 >3000 >70 1270
43 1200 120 >3000 >70 692
44 >3000 >80 >3000 >30 8780
3 30000 90 ND ND 260
1 2200 110 ND ND ND
aSee Experimental Section and the legend to Table 3 for details.
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potent antidepressant-like effect. Moreover, 43 was also active
at an orally administered dose of 5 mg/kg.
Broad Screening at Other Neurotransmitter Recep-
tors and Transporters. A broad-range screening study was
carried out for compound 43 to further determine its effects at
10 μM on about 45 other CNS neurotransmitter receptors and
transporters, including serotonin receptors, dopamine recep-
tors, GABA receptors, biogenic amine transporters, adrenergic
receptors, muscarinic receptors, opioid receptors, sigma
receptors, and histamine receptors (NIMH-PDSP, University
of North Carolina, Chapel Hill). No inhibition caused by 10
μM of compound 43 was greater than 50% in the preliminary
binding screen, indicating that 43 has no significant activity at
these targets (see Supporting Information).
Preliminary in Vitro ADME-Tox Profile. Compound 43
showed good properties in assays for cytochrome P450 (CYP)
inhibition, metabolic stability, and plasma protein binding (SRI,
Stanford Research Institute), as well as hERG (human ether-a-
go-go-related gene) inhibition (NIMH-PDSP) (see the
Supporting Infornation).
CYP Inhibition. The inhibitory effect of 43 on in vitro CYP
activity in human liver microsomes was screened using a high-
throughput multiple CYP assay for CYP1A2, CYP2B6,
CYP2C9, CYP2C19, CYP2D6, and CYP3A4. In the presence
of 1 μM and 10 μM of 43, none of these CYP isoforms’ activity
was reduced to less than 70% of the control, suggesting that 43
will not alter the metabolism of other xenobiotics or
endogenous compounds that are substrates for the CYP
isoforms tested.
Metabolic Stability. The metabolic stability of 43 was
studied using human and mouse liver microsomes. The test
article was incubated at two concentrations (1 μM and 10 μM),
and aliquots (100 μL) were removed at various time points (0,
15, 30, and 60 min) for analysis by LC-MS/MS. This study
showed that liver microsomes from both species caused a time-
dependent decrease in parent drug at both concentrations.
Human liver microsomes metabolized 43 to a greater extent in
60 min than mouse liver microsomes; 53.4% and 67.2% of the
parent drug remained unchanged at 1 μM and 10 μM,
respectively. Incubation with mouse liver microsomes resulted
in 67.5% and 73.7% of 43 remaining unchanged after 60 min
incubation at 1 μM and 10 μM, respectively.
PPB (Plasma Protein Binding). The binding of 43 to
proteins in human and mouse plasma was determined using
equilibrium dialysis. Binding of 43 was evaluated at
concentrations of 0, 0.1, 1, and 10 μM. The mean percentage
of binding of this compound to human plasma ranged from
8.2% to 17.7%. Its mean percentage of binding to mouse
plasma ranged from 12.9% to 19.3%.
hERG Inhibition. HEK293 cells stably expressing recombi-
nant human hERG were used in a fluorescence-based
membrane potential assay. The observed hERG inhibition of
43 at 10 μM was similar to that of the negative control, giving
0% hERG blockade.
■ CONCLUSIONS
In the present study, a new series of isoxazole ether nAChR
ligands have been identified, and their preliminary SAR has
been explored. In the PDSP binding study, most of the 5-
alkoxyisoxazole ligands were found to bind to the rat α4β2-
nAChR with a significantly higher affinity than to the α3β4*-
nAChR. Compound 43 was identified as the lead compound
from this series as it displayed favorable in vitro nAChR binding
affinities. The functional potency of isoxazole 43 at the α4β2-
nAChR is similar to that of compound 1, but it has higher
efficacy, helping to distinguish it from compound 1. When
tested in vivo, compound 43 demonstrated a potent
antidepressant-like activity at both 5 mg/kg and 1 mg/kg ip,
and was orally active at 5 mg/kg in the mouse forced swim test.
Preliminary in vitro ADME-Tox characterization further
suggested promising drug-like properties of 43. The PDSP
broad range screening indicated that compound 43 was highly
selective for nAChRs and did not have significant binding
affinity to the other 45 neurotransmitter receptors and
transporters tested.
It remains unclear whether activity at the α3β4*-nAChR
subtype is an attribute or a detriment for treatment of
depression. Further studies are required to fully understand the
importance of α3β4*-nAChR involvement in depression. Our
previously reported nicotinic ligands such as sazetidine-A and
3-alkoxy-5-aminopyridine derivatives, that contain appropriate
substituents in the 5-position of their pyridine rings, exhibited
improved selectivity for β2- over β4-containing nAChRs.6,52−55
Considering that the present isoxazole ligands are easily
accessible through substitution reactions performed upon a
preassembled isoxazole building block, the 5-alkoxyisoxazole
scaffold should be a useful starting point for a broader
optimization campaign to discover more α4β2-selective nAChR
ligands, perhaps importantly with higher efficacy than
Figure 4. Compound 43 reduced immobility in the mouse forced swim test at low (1 and 5 mg/kg) doses. The SSRI, sertraline, produced the
expected decrease in immobility. (ANOVAs: Fs > 6.845, ps < 0.0010. *Fisher’s PLSD posthoc test: ps < 0.05 vs vehicle). All drugs were administered
intraperitoneally (A) or orally (B); n = 9−10/group). Compound 43 reduced immobility in the forced swim test in mice at 5 mg/kg, but was inactive
at 1 mg/kg when administered orally.
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compound 1, that may in due course lead to a novel treatment
option for depression.
■ EXPERIMENTAL SECTION
General Methods. Starting materials, reagents, and solvents were
purchased from commercial suppliers and used without further
purification, unless otherwise stated. Anhydrous THF and CH2Cl2
were obtained by distillation over sodium wire or CaH2, respectively.
All nonaqueous reactions were run under an argon atmosphere with
exclusion of moisture from reagents, and all reaction vessels were
oven-dried. The progress of reactions was monitored by TLC on SiO2.
Spots were visualized by their quenching of the fluorescence of an
indicator admixed to the SiO2 layer, or by dipping into KMnO4
solution followed by heating. SiO2 for column chromatography (CC)
was of 230−400 mesh particle size, and an EtOAc/hexane mixture or
gradient was used unless stated otherwise. 1H NMR spectra were
recorded at a spectrometer frequency of 300 or 400 MHz, 13C NMR
spectra at 75 or 100 MHz. 1H chemical shifts are reported in δ (ppm)
using the δ 7.26 signal of CDCl3, the δ 4.80 signal of D2O, the δ 3.31
signal of CD3OD, or the δ 2.50 signal of DMSO-d6 as internal
standards. 13C chemical shifts are reported in δ (ppm) using the δ
77.23 signal of CDCl3, the δ 49.15 signal of CD3OD, or the δ 39.51
signal of DMSO-d6 as internal standards.
13C NMR spectra in D2O
were not adjusted. Purities of final compounds (>98%) were
established by analytical HPLC, which was carried out on an Agilent
1100 HPLC system with a Synergi 4 μ Hydro-RP 80A column, with
detection at 220 or 254 nm on a variable wavelength detector
G1314A; flow rate = 1.4 mL/min; gradient of 0 to 100% methanol in
water (both containing 0.05 vol% of TFA) in 18 min. Final products
were purified by preparative HPLC under the following conditions:
column, ACE AQ, 250 × 20 mm; flow, 17 mL/min; all solvents
containing 0.05 vol% TFA; UV detection at 254 and 220 nm; Gradient
I: 25−100% MeOH in water in 30 min, 100% for 5 min, return to 25%
in 4 min, and equilibration at 25% for 1 min; Gradient II: 8−100%
MeOH in water in 30 min, 100% for 5 min, return to 25% in 4 min,
and equilibration at 8% for 1 min; Gradient III: 0−50% MeOH in
water in 20 min, to 100% in 5 min, 100% for another 5 min, return to
0% in 5 min, and equilibration at 0% for 1 min.
General Procedure for the Deprotection of N-Boc-Amines to
Afford TFA Salts (Method A). To a solution of the N-Boc protected
precursor (1 mmol) in CH2Cl2 (10 mL) was added TFA (1 mL)
under argon with ice cooling. The mixture was stirred overnight at rt.
After the solvent was evaporated, the residue was dissolved in distilled
water (5 mL). The solution was filtered over a syringe filter
(polytetrafluoroethylene, 17 mm diameter, 0.45 μm pore size), then
concentrated to 2−3 mL under reduced pressure at 30 °C bath
temperature. The crude product was purified by preparative HPLC.
After the solvent was evaporated, the residue was dissolved in distilled
water (about 2−3 mL). The solution was lyophilized to obtain the
TFA salt.
General Procedure for the Mitsunobu Reaction of 1-(tert-
Butoxycarbonyl)-2(S)-azetidinylmethanol (15) or 1-(tert-Butox-
ycarbonyl)-2(S)-pyrrolidinylmethanol (25) with Hydroxyisox-
azoles to Afford Alkoxyisoxazoles (Method B). To a stirred
solution of a hydroxyisoxazole (1 mmol), alcohol 15 or 25 (1.2
mmol), and PPh3 (1.5 mmol) in anhydrous THF (20 mL) was added
diethyl azodicarboxylate or diisopropyl azodicarboxylate (1.5 mmol)
dropwise. After stirring overnight at rt, the solvent was evaporated, and
the residue was dissolved in EtOAc. The solution was washed with
water (20 mL) and brine (15 mL), dried over Na2SO4, filtered, and
concentrated under a vacuum. The residue was purified by CC on
SiO2 to give the alkoxyisoxazole.
General Procedure for the Reduction of Isoxazolecarboxylic
Acid Esters to Alcohols (Method C). To a solution of an
isoxazolecarboxylic acid ester (1 mmol) in anhydrous THF (20 mL)
was added LiBH4 (4 mmol) with ice cooling under Ar. After stirring
overnight at rt, saturated aqueous NH4Cl solution was added with ice
cooling. Extraction with EtOAc, drying over Na2SO4, and CC on SiO2
gave the alcohol.
General Procedure for the Preparation of Iodides from
Alcohols (Method D). To a stirred solution of an isoxazolylmethanol
(1 mmol), imidazole (1.5 mmol), and PPh3 (1.5 mmol) in anhydrous
PhMe (8 mL) was added I2 (1.5 mmol) with ice cooling under Ar.
After stirring overnight at rt, the solvent was evaporated. The residue
was purified by CC on SiO2 to give the iodide.
General Procedure for the Preparation of Phenyl Ethers
from Iodides (Method E). To a stirred solution of an (iodomethyl)-
isoxazole (1 mmol) and phenol (2 mmol) in anhydrous DMF (4 mL)
was added K2CO3 (6 mmol) under Ar. After stirring overnight at rt,
saturated aqueous NH4Cl solution was added. The mixture was
extracted with EtOAc (2 × 15 mL), and the combined organic phases
were washed with water (3 × 10 mL), dried over Na2SO4, and
evaporated. The residue was purified by CC on SiO2 to give the
product.
General Procedure for the Preparation of Alkyl Ethers from
Alcohols (Method F). To a stirred solution of an isoxazolylmethanol
(1 mmol) in anhydrous DMF (2 mL) was added NaH (60%
dispersion in oil, 1.9 mmol) with ice cooling under Ar. After stirring
for 30 min at rt, alkyl halide (1 mmol) was added. Stirring was
continued for 2 h at rt, then the reaction was quenched with saturated
aqueous NH4Cl solution with ice cooling. The mixture was extracted
with EtOAc (2 × 15 mL), and the combined organic phases were
washed with water (3 × 10 mL), dried over Na2SO4, and evaporated.
The residue was purified by CC on SiO2 to give the product.
General Procedure for the Preparation of Amines from
Iodides (Method G). To a solution of an (iodomethyl)isoxazole (1
mmol) in anhydrous CH3CN (10 mL) were added at rt K2CO3 (6
mmol) and amine (4 mmol). After stirring overnight, the reaction
mixture was concentrated. The residue was purified by CC on SiO2
(CH2Cl2/MeOH) to obtain the product.
General Procedure for the Preparation of Carbamates from
Alcohol 29 (Method H). A solution of 29 (1 mmol), isocyanate (2
mmol), and 4-(dimethylamino)pyridine (0.1 mmol) in anhydrous
toluene (5 mL) was stirred at 80 °C under Ar for 5 h. The solvent was
removed under reduced pressure, and the residue was purified by CC
on SiO2 (acetone/hexane) to obtain the product.
3-[[1-(tert-Butoxycarbonyl)-2(S)-azetidinyl]methoxy]-5-iso-
xazolylmethanol (17). This compound was obtained from 1-(tert-
butoxycarbonyl)-2(S)-azetidinylmethanol and 3-hydroxyisoxazole-5-
carboxylic acid methyl ester in two steps as a colorless oil in 84%
yield employing Method B and Method C. 1H NMR (400 MHz,
CDCl3) δ 6.57 (s, 1H), 4.58−4.54 (m, 1H), 4.48 (m, 1H), 4.35 (d,
2H, J = 10.8 Hz), 3.92 (s, 1H), 3.84 (t, 2H, J = 7.6 Hz), 2.33−2.28 (m,
1H), 2.22−2.18 (m, 1H), 1.39 (s, 9H).
3-[(2(S)-Azetidinyl)methoxy]-5-isoxazolylmethanol (18). This
compound was obtained from 17 employing Method A and Gradient
III. Colorless oil; yield 51%; purity 99.8%. [α]D
20 3.1 (c = 0.42,
MeOH); 1H NMR (400 MHz, D2O) δ 6.20 (s, 1H), 4.95 (m, 1H),
4.66 (s, 2H), 4.60−4.52 (m, 2H), 4.15 (dd, 1H, J = 9.2, 18.8 Hz), 4.04
(dd, 1H, J = 9.2, 18.4 Hz), 2.67 (q, 2H, J = 8.8 Hz); 13C NMR (100
MHz, D2O) δ 172.8, 171.0, 162.3 (TFA), 115.5 (TFA), 93.0, 67.6,
58.5, 54.7, 43.1, 19.8. Anal. Calcd for C8H12N2O3·1.0TFA·0.25H2O
(FW 305): C, 39.68; H, 4.49; N, 9.25; F, 18.98. Found: C, 39.94; H,
4.25; N, 8.92; F, 18.98.
3-[(2(S)-Azetidinyl)methoxy]-5-(phenoxymethyl)isoxazole
(19). This compound was obtained from 17 and phenol employing
Methods D, E, and A and Gradient I. Colorless solid; yields of the
individual steps 93%, 89%, and 81%; purity ∼ 100%. [α]D20 1.2 (c =
0.68, MeOH); 1H NMR (400 MHz, D2O) δ 7.02−7.00 (m, 2H), 6.70
(m, 3H), 6.01 (s, 1H), 4.75−4.70 (m, 3H), 4.34 (s, 2H), 4.02 (m, 1H),
3.90 (m, 1H), 2.52−2.43 (m, 2H); 13C NMR (100 MHz, D2O) δ
170.7, 168.8, 161.9 (TFA), 156.8, 129.1, 121.3, 115.9 (TFA), 114.2,
94 .7 , 67 .5 , 60 .3 , 58 .1 , 43 .0 , 19 .8 . Ana l . Ca lcd for
C14H16N2O3·1.1TFA·0.55H2O (FW 398): C, 49.18; H, 4.64; N,
7.08; F, 15.85. Found: C, 48.89; H, 4.27; N, 7.06; F, 15.90.
3-[(2(S)-Azetidinyl)methoxy]-5-[(hexyloxy)methyl]isoxazole
(20). This compound was obtained from 17 and MeI employing
Methods F and A and Gradient I. Colorless oil; yields of the individual
steps 84% and 76%; purity ∼ 100%. [α]D20 2.8 (c = 0.14, MeOH); 1H
NMR (400 MHz, D2O) δ 6.10 (s, 1H), 4.90−4.86 (m, 1H), 4.47−4.43
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(m, 2H), 4.41 (s, 2H), 4.09 (m, 1H), 4.02−3.95 (m, 1H), 3.45 (t, 2H,
J = 6.8 Hz), 2.64−2.52 (m, 2H), 1.53−1.48 (m, 2H), 1.28−1.23 (m,
6H), 0.83−0.80 (m, 3H); 13C NMR (100 MHz, D2O) δ 170.8, 170.4,
161.8 (TFA), 120.2, 115.8 (TFA), 94.1, 70.7, 67.5, 62.8, 58.2, 43.1,
30 .9 , 28 .6 , 24 .9 , 21 .8 , 19 .9 , 13 .0 . Ana l . Ca lcd for
C14H24N2O3·1.0TFA·0.05H2O (FW 385): C, 50.14; H, 6.60; N,
7.31; F, 14.87. Found: C, 49.93; H, 6.26; N, 7.18; F, 14.56.
3-[(2(S)-Azetidinyl)methoxy]-5-[(cyclopropylmethoxy)-
methyl]isoxazole (21). This compound was obtained from 17 and
(bromomethyl)cyclopropane employing Methods F and A and
Gradient II. Colorless oil; yields of the individual steps 77% and
59%; purity 99.8%. [α]D
20 −0.1 (c = 2.8, MeOH); 1H NMR (400
MHz, D2O) δ 6.25 (s, 1H), 4.93 (m, 1H), 4.60 (s, 2H), 4.57−4.51 (m,
2H), 4.12 (m, 1H), 4.05 (m, 1H), 3.40 (d, 2H, J = 7.2 Hz), 2.69−2.62
(m, 2H), 1.04 (m, 1H), 0.56−0.52 (m, 2H), 0.22−0.18 (m, 2H); 13C
NMR (100 MHz, D2O) δ 170.9, 170.2, 162.2 (TFA), 115.9 (TFA),
94.6, 75.7, 67.6, 62.2, 58.4, 43.2, 19.9, 9.2, 2.1. Anal. Calcd for
C12H18N2O3·1.1TFA·0.65H2O (FW 378): C, 45.43; H, 5.48; N, 7.46;
F, 16.70. Found: C, 45.20; H, 5.19; N, 7.31; F, 16.84.
3-[[1-(tert-Butoxycarbonyl)-2(S)-azetidinyl]methoxy]-5-
methylisoxazole (23). This compound was obtained from 1-(tert-
butoxycarbonyl)-2(S)-azetidinylmethanol and 3-hydroxy-5-methylisox-
azole as a pale-yellow solid in 67% yield employing Method B. 1H
NMR (400 MHz, CDCl3) δ 5.63 (s, 1H), 4.48−4.42 (m, 2H), 4.29−
4.26 (m, 2H), 3.83 (t, 2H, J = 9.4 Hz), 2.31−2.16 (m, 5H), 1.39 (s,
9H); 13C NMR (100 MHz, D2O) δ 172.3, 170.6, 156.3, 93.1, 79.8,
69.9, 60.2, 47.0, 28.5, 21.9, 19.0, 13.0.
3-[(2(S)-Azetidinyl)methoxy]-5-methylisoxazole (24). This
compound was obtained employing Method A and Gradient III.
Colorless oil; yield 58%; purity 99.7%. [α]D
20 −0.2 (c = 2.4, MeOH);
1H NMR (400 MHz, D2O) δ 5.90 (s, 1H), 4.98 (m, 1H), 4.46 (m,
1H), 4.12 (m, 1H), 4.00 (m, 1H), 2.66−2.58 (m, 2H), 2.30 (s, 3H);
13C NMR (100 MHz, D2O) δ 172.3, 171.2, 162.1 (TFA), 115.9
(TFA), 92.4, 67.3, 58.5, 43.2, 19.8, 11.6. Anal. Calcd for
C8H12N2O2·1.15TFA·0.55H2O (FW 312): C, 40.01; H, 4.64; N,
9.06; F, 21.20. Found: C, 39.88; H, 4.43; N, 9.11; F, 21.41.
5-[(1-(tert-Butoxycarbonyl)-2(S)-azetidinyl)methoxy]-
isoxazole-3-carboxylic Acid Ethyl Ester (27). This compound was
obtained from 1-(tert-butoxycarbonyl)-2(S)-azetidinylmethanol and 5-
hydroxyisoxazole-3-carboxylic acid ethyl ester (Princeton Bio) as a
pale-yellow solid in 55% yield employing Method B. 1H NMR (400
MHz, CDCl3) δ 5.71 (s, 1H), 4.52 (m, 2H), 4.41 (q, 2H, J = 7.2 Hz),
4.31 (dd, 1H, J = 2.4, 10.0 Hz), 3.89−3.84 (m, 2H), 1.41 (s, 9H), 1.25
(t, 3H, J = 7.2 Hz).
5-[(1-(tert-Butoxycarbonyl)-2(S)-pyrrolidinyl)methoxy]-
isoxazole-3-carboxylic Acid Ethyl Ester (28). This compound was
obtained from 1-(tert-butoxycarbonyl)-2(S)-pyrrolidinylmethanol and
5-hydroxyisoxazole-3-carboxylic acid ethyl ester as a pale-yellow solid
in 65% yield employing Method B. 1H NMR (400 MHz, CDCl3; two
rotamers about the N-Boc bond in an approximate ratio of 1:1) δ 5.66
(br, 1H), 4.35 (q, 2H, J = 7.2 Hz), 4.28 (br, 1.5H), 4.07 (br, 1.5H),
3.29 (br, 2H), 2.01−1.83 (m, 4H), 1.41 (s, 9H), 1.34 (t, 3H, J = 7.2
Hz).
5-[(1-(tert-Butoxycarbonyl)-2(S)-pyrrolidinyl)methoxy]-3-
isoxazolylmethanol (30). This compound was obtained from 5-[[1-
(tert-butoxycarbonyl)-2(S)-pyrrolidinyl]methoxy]isoxazole-3-carbox-
ylic acid ethyl ester as a pale-yellow solid in 94% yield employing
Method C. 1H NMR (400 MHz, CDCl3; two rotamers about the N-
Boc bond in an approximate ratio of 1:1) δ 5.28 (br, 0.5H), 5.22 (br,
0.5H), 4.43 (d, 2H, J = 5.6 Hz), 4.25−3.97 (m, 4H), 3.22 (br, 2H),
1.90−1.75 (m, 4H), 1.32 (s, 9H).
5-[(2(S)-Azetidinyl)methoxy]-3-isoxazolylmethanol (31). 5-
[[1-(tert-Butoxycarbonyl)-2(S)-azetidinyl]methoxy]-3-isoxazolylme-
thanol (29) was obtained from 27 as a pale-yellow solid in quantitative
yield employing Method C. The title compound 31 was obtained from
29 employing Method A and Gradient III. Colorless oil; yield 67%;
purity 100%. [α]D
20 −3.0 (c = 1.2, MeOH); 1H NMR (400 MHz,
D2O) δ 5.52 (s, 1H), 4.85 (m, 1H), 4.53−4.45 (m, 4H), 4.06 (m, 1H),
3.95 (m, 1H), 2.60−2.53 (m, 2H); 13C NMR (100 MHz, D2O) δ
172.3, 166.1, 162.3 (TFA), 115.9 (TFA), 77.4, 69.8, 58.1, 55.5, 43.2,
19.8. Anal. Calcd for C8H12N2O3·1.4TFA (FW 344): C, 37.73; H,
3.93; N, 8.15; F, 23.21. Found: C, 37.82; H, 4.10; N, 8.47; F, 23.26.
5-[(2(S)-Azetidinyl)methoxy]-3-(phenoxymethyl)isoxazole
(32). The title compound was obtained from 29 employing Method A
and Gradient II. Colorless solid; yield 38%; purity 98.9%. [α]D
20 −1.0
(c = 1.1, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.30−7.26 (m,
2H), 7.00−6.94 (m, 3H), 5.69 (s, 2H), 4.90 (m, 1H), 4.59 (m, 1H),
4.52 (m, 1H), 4.09 (m, 1H), 4.00 (m, 1H), 2.62 (m, 1H); 13C NMR
(100 MHz, CD3OD) δ 172.6, 163.0, 160.1 (TFA), 157.7, 128.8, 120.8,
115.9 (TFA), 114.1, 77.4, 69.9, 61.3, 58.0, 42.8, 19.9. Anal. Calcd for
C14H16N2O3·1.55TFA·0.45H2O (FW 445): C, 46.14; H, 4.18; N, 6.29;
F, 19.85. Found: C, 45.98; H, 4.04; N, 6.39; F, 20.03.
3-(Phenoxymethyl)-5-[(2(S)-pyrrolidinyl)methoxy]isoxazole
(33). This compound was obtained employing Method A and
Gradient II. Colorless solid; yield 75%; purity 100%. [α]D
20 −1.7 (c
= 1.5, MeOH); 1H NMR (400 MHz, CD3OD) δ 7.30−7.26 (m, 2H),
7.00−6.94 (m, 3H), 5.69 (s, 2H), 5.04 (s, 2H), 4.62 (m, 1H), 4.40 (m,
1H), 4.06 (m, 1H), 3.36 (t, 2H, J = 7.2 Hz), 2.26 (m, 1H), 2.13−2.05
(m, 2H), 1.87 (m, 1H); 13C NMR (100 MHz, CD3OD) δ 172.3,
162.8, 160.0 (TFA), 157.5, 128.6, 120.6, 115.7 (TFA), 113.8, 77.1,
69 .8 , 61 .1 , 57 .7 , 45 .0 , 25 .1 , 22 .7 . Ana l . Ca lcd for
C15H18N2O3·1.2TFA·0.35H2O (FW 417): C, 50.06; H, 4.80; N,
6.71; F, 16.38. Found: C, 50.22; H, 4.73; N, 6.67; F, 16.14.
3-(Anilinomethyl)-5-[(2(S)-azetidinyl)methoxy]isoxazole
(34). The title compound was obtained from 29 employing Methods
D, G, and A and Gradient III. Pale-yellow oil; yields of the individual
steps 76%, quantitative and 35%; purity 99.9%. [α]D
20 −2.7 (c = 0.79,
MeOH); 1H NMR (400 MHz, D2O) δ 7.52 (t, 2H, J = 7.6 Hz), 7.44
(t, 1H, J = 7.4 Hz), 7.35 (d, 2H), 5.61 (s, 1H), 4.94−4.92 (m, 1H),
4.63 (s, 1H), 4.58−4.53 (m, 2H), 4.17−4.10 (m, 1H), 4.06−3.99 (m,
1H), 2.70−2.60 (m, 2H); 13C NMR (100 MHz, D2O) δ 172.8, 162.5
(TFA), 159.0, 135.7, 129.8, 127.8, 120.7, 115.9 (TFA), 78.8, 69.9,
58.0, 44.6, 43.2, 19.7. Anal. Calcd for C14H17N3O2·1.8TFA·1.25 H2O
(FW 487): C, 43.40; H, 4.41; N, 8.63; F, 21.06. Found: C, 43.34; H,
4.27; N, 8.76; F, 21.09.
5-[(2(S)-Azetidinyl)methoxy]-3-[(4-fluoroanilino)methyl]-
isoxazole (35). This compound was obtained from 29 employing
Methods D, G, and A and Gradient III. Pale-yellow oil; yields of the
individual steps 76%, quantitative, and 74%; purity 99.5%. [α]D
20 −2.0
(c = 1.4, MeOH); 1H NMR (400 MHz, D2O) δ 7.13−7.08 (m, 4H),
5.58 (s, 1H), 4.92 (m, 1H), 4.63 (s, 1H), 4.58−4.54 (m, 2H), 4.44 (s,
2H), 4.13 (m, 1H), 4.02 (m, 1H), 2.68−2.59 (m, 2H); 13C NMR (100
MHz, D2O) δ 172.5, 162.2, 162.2 (TFA), 158.7 (d, JC−F = 20.3 Hz),
137.5, 119.1 (d, JC−F = 8.3 Hz), 115.9 (TFA), 115.9 (d, JC−F = 238.4
Hz), 78.3, 69.8, 58.0, 43.2, 42.5, 19.7. Anal. Calcd for
C14H16FN3O2·1.4TFA·0.55H2O (FW 447): C, 45.16; H, 4.17; N,
9.40; F, 22.11. Found: C, 45.17; H, 4.13; N, 9.35; F, 22.09.
5-[(2(S)-Azetidinyl)methoxy]-3-[(N-phenylcarbamoyloxy)-
methyl]isoxazole (36). This compound was obtained from 29 and
phenyl isocyanate employing Methods H and A and Gradient II.
Colorless oil; yields of the individual steps 93% and 40%; purity 99.8%.
[α]D
20 −3.7 (c = 3.4, MeOH); 1H NMR (400 MHz, D2O) δ 7.22 (d,
2H, J = 8.0 Hz), 7.09 (t, 2H, J = 8.0 Hz), 6.87 (t, 2H, J = 7.4 Hz), 5.39
(s, 1H), 4.93 (s, 2H), 4.74 (m, 1H), 4.31−4.25 (m, 2H), 4.01 (m, 1H),
3.90−3.85 (m, 1H), 2.55−2.36 (m, 2H); 13C NMR (100 MHz, D2O)
δ 172.2, 162.2, 162.0 (TFA), 153.8, 137.0, 128.5, 123.4, 118.8, 115.9
(TFA), 77.7, 69.7, 58.0, 57.8, 43.1, 20.0. Anal. Calcd for
C15H17N3O4·1.55TFA·2.35 H2O (FW 552): C, 41.62; H, 4.49; N,
8.04; F, 16.91. Found: C, 41.51; H, 4.46; N, 8.19; F, 16.94.
5-[(2(S)-Azetidinyl)methoxy]-3-[(N-ethylcarbamoyloxy)-
methyl]isoxazole (37). This compound was obtained from 29 and
ethyl isocyanate employing Methods H and A and Gradient III.
Colorless oil; yields of the individual steps 99% and 50%; purity 99.6%.
[α]D
20 −3.0 (c = 2.8, MeOH); 1H NMR (400 MHz, D2O) δ 5.62 (s,
1H), 5.04 (s, 2H), 4.96 (m, 1H), 4.63−4.55 (m, 2H), 4.15 (m, 1H),
4.04 (m, 1H), 3.13 (q, J = 7.2 Hz, 2H), 2.72−2.62 (m, 2H), 1.08 (t, J =
7.2 Hz, 3H); 13C NMR (100 MHz, D2O) δ 172.4, 163.1, 162.2 (TFA),
157.0, 115.9 (TFA), 77.7, 69.9, 58.1, 58.0, 43.2, 35.2, 19.8, 13.6. Anal.
Calcd for C11H17N3O4·1.4TFA·0.95H2O (FW 432): C, 38.37; H, 4.74;
N, 9.73; F, 18.47. Found: C, 38.13; H, 4.86; N, 9.97; F, 18.63.
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5 - [ ( 2 ( S ) - A z e t i d i n y l ) m e t h o x y ] - 3 - [ ( N -
cyclopentylcarbamoyloxy)methyl]isoxazole (38). This com-
pound was obtained from 29 and cyclopentyl isocyanate employing
Methods H and A and Gradient III. Colorless oil; yields of the
individual steps 94% and 40%; purity 99.6%. [α]D
20 −2.2 (c = 1.7,
MeOH); 1H NMR (400 MHz, D2O) δ 5.63 (s, 1H), 5.07 (s, 2H), 4.96
(m, 1H), 4.65−4.57 (m, 2H), 4.13 (m, 1H), 4.06 (m, 1H), 3.87 (m
1H), 2.70−2.64 (m, 2H), 1.91−1.85 (m, 2H), 1.66−1.57 (m, 4H),
1.49−1.43 (m, 2H); 13C NMR (100 MHz, D2O) δ 172.4, 163.1, 162.4
(TFA), 156.7, 115.7 (TFA), 77.7, 69.8, 58.0, 57.9, 52.3, 43.2, 31.8,
22.7, 19.7. Anal. Calcd for C14H21N3O4·1.7TFA·1.65H2O (FW 522):
C, 40.28; H, 5.05; N, 8.10; F, 18.67. Found: C, 40.09; H, 4.81; N, 8.28;
F, 18.81.
5-[(2(S)-Azetidinyl)methoxy]-3-(fluoromethyl)isoxazole Tri-
fluoroacetate (39). To a solution of Et2NSF3 (0.22 mL, 1.7
mmol) in anhydrous CH2Cl2 (10 mL) was added at −78 °C 5-[[1-
(tert-butoxycarbonyl)-2(S)-azetidinyl]methoxy]-3-isoxazolylmethanol
(425 mg, 1.5 mmol) in CH2Cl2 (5 mL) under Ar. The solution was
stirred for 2 h at −78 °C, then allowed to warm to rt. After the
reaction was quenched with saturated aqueous NaHCO3 solution, the
phases were separated. The aqueous layer was extracted with CH2Cl2
(2 × 10 mL), and the combined organic phases were washed with
water (5 mL), dried over Na2SO4, and concentrated. The residue was
subjected to CC on SiO2 to obtain 5-[(1-(tert-butoxycarbonyl)-2(S)-
azetidinyl)methoxy]-3-(fluoromethyl)isoxazole (70 mg, 16%) as a
colorless oil. 1H NMR (400 MHz, CDCl3) δ 5.39 (s, 1H), 5.32 (s,
1H), 5.21 (s, 1H), 4.48−4.44 (m, 2H), 4.26 (m, 1H), 3.87−3.78 (m,
2H), 2.35−2.22 (m, 2H), 1.39 (s, 9H); 13C NMR (100 MHz, CDCl3)
δ 174.2, 161.9 (d, JC−F = 22.4 Hz), 156.1, 80.1, 77.2, 76.6 (d, JC−F =
165.9 Hz), 72.6, 59.1, 47.3, 28.4, 18.7.
This title compound was obtained employing Method A and
Gradient III. Colorless oil; yield 46%; purity 99.4%. [α]D
20 −2.8 (c =
1.9, MeOH); 1H NMR (400 MHz, D2O) δ 5.74 (s, 1H), 5.48 (s, 1H),
5.36 (s, 1H), 4.97 (m, 1H), 4.66−4.58 (m, 2H), 4.15 (m, 1H), 4.06
(m, 1H), 2.72−2.64 (m, 2H); 13C NMR (100 MHz, D2O) δ 172.6,
162.3 (TFA), 162.3 (d, JC−F = 20.3 Hz), 115.9 (TFA), 77.8, 76.2 (d,
JC−F = 162.3 Hz), 70.0, 58.1, 43.2, 19.8;
19F NMR (376 MHz, D2O) δ
−76, −222. Anal. Calcd for C8H11FN2O2·1.05TFA·0.85 H2O (FW
323): C, 37.77; H, 4.31; N, 8.72; F, 24.54. Found: C, 37.50; H, 4.03;
N, 8.65; F, 24.32.
5-[[1-(tert-Butoxycarbonyl)-2(S)-azetidinyl]methoxy]-3-
methylisoxazole (41). This compound was obtained from 15 and 3-
methylisoxazol-5(4H)-one morpholine salt (40; Fluka) as a pale-
yellow solid in 67% crude yield employing Method B. 1H NMR (400
MHz, CDCl3) δ 5.07 (s, 1H), 4.45−4.39 (m, 2H), 4.18 (dd, 2H, J =
10.0, 1.5 Hz), 3.78 (t, 2H, J = 8.4 Hz), 2.30−2.21 (m, 2H), 2.13 (s,
3H), 1.36 (s, 9H).
5-[(2(S)-Azetidinyl)methoxy]-3-methylisoxazole (43). This
compound was obtained from 41 employing Method A and Gradient
III. Colorless oil; yield 38%; purity 100%. [α]D
20 −1.9 (c = 0.47,
MeOH); 1H NMR (400 MHz, D2O) δ 5.46 (s, 1H), 4.56 (m, 1H),
4.39 (m, 1H), 4.10 (m, 1H), 3.40 (t, 2H, J = 7.2 Hz), 2.27 (m, 1H),
2.20 (s, 3H), 2.16−2.06 (m, 2H), 1.90 (m, 1H); 13C NMR (100 MHz,
D2O) δ 171.9, 164.0, 162.3 (TFA), 115.9 (TFA), 79.2, 69.6, 58.1, 43.1,
19.8, 10.9. Anal. Calcd for C8H12N2O2·1.1TFA·0.25H2O (FW 300): C,
41.09; H, 4.60; N, 9.40; F, 21.03. Found: C, 40.94; H, 4.40; N, 9.23; F,
21.02.
3-Methyl-5-[(2(S)-pyrrolidinyl)methoxy]isoxazole (44). The
title compound was obtained from 25 and 40 employing Method B
and A and Gradient III. Colorless oil; yields of the individual steps
58% and 38%; purity 99.5%. [α]D
20 6.7 (c = 2.6, MeOH); 1H NMR
(400 MHz, D2O) δ 5.46 (s, 1H), 4.56 (m, 1H), 4.39 (m, 1H), 4.10 (m,
1H), 3.40 (t, 2H, J = 7.2 Hz), 2.27 (m, 1H), 2.20 (s, 3H), 2.16−2.06
(m, 2H), 1.90 (m, 1H); 13C NMR (100 MHz, D2O) δ 171.9, 164.0,
162.3 (TFA), 115.9 (TFA), 79.2, 69.7, 57.9, 45.5, 25.2, 22.9, 10.9.
Anal. Calcd for C9H14N2O2·1.1TFA·0.8H2O (FW 324): C, 41.77; H,
5.23; N, 8.70; F, 19.47. Found: C, 41.57, H, 4.85; N, 8.58; F, 19.13.
In Vitro Binding Studies. [3H]Epibatidine competition studies
and broad-range screening were carried out by the National Institute
of Mental Health’s Psychoactive Drug Screening Program, Contract #
HHSN-271-2008-00025-C (NIMH PDSP). For experimental details
please refer to the PDSP Web site http://pdsp.med.unc.edu/
Cell Lines and Culture. Cell lines naturally or heterologously
expressing specific, functional, human nAChR subtypes were used.
The human clonal cell line TE671/RD naturally expresses human
muscle-type α1*-nAChRs, containing α1, β1, γ, and δ subunits, with
function detectable using 86Rb+ efflux assays.56 The human neuro-
blastoma cell line SH-SY5Y naturally expresses autonomic α3β4*-
nAChRs, containing α3, β4, probably α5, and sometimes β2 subunits,
and also displays function detectable using 86Rb+ efflux assays.57 SH-
SY5Y cells also express homopentameric α7-nAChRs; however, their
function is not detected in the 86Rb+ efflux assay under the conditions
used. SH-EP1 human epithelial cells stably transfected with human α4
and β2 subunits (SH-EP1-hα4β2 cells) have been established and
characterized with both ion flux and radioligand binding assays.58
TE671/RD, SH-SY5Y, and transfected SH-EP1 cell lines were
maintained as low passage number (1−26 from our frozen stocks)
cultures to ensure stable expression of native or heterologously
expressed nAChRs as previously described.56 Cells were passaged once
a week by splitting just-confluent cultures 1/300 (TE671/RD), 1/10
(SH-SY5Y), or 1/40 (transfected SH-EP1) in serum-supplemented
medium to maintain log-phase growth.
86Rb+ Efflux Assays. Function of nAChR subtypes was
investigated using an established 86Rb+ efflux assay protocol.56 The
assay is specific for nAChR function under the conditions used, for
example, giving identical results in the presence of 100 nM atropine to
exclude possible contributions of muscarinic acetylcholine receptors.
Cells harvested at confluence from 100 mm plates under a stream of
fresh medium only (SH-SY5Y cells) or after mild trypsinization (Irvine
Scientific, USA; for TE671/RD or transfected SH-EP1 cells) were
then suspended in complete medium and evenly seeded at a density of
1.25−2 confluent 100 mm plates per 24-well plate (Falcon; ∼100−125
mg of total cell protein per well in a 500 μL volume; poly L-lysine-
coated for SH-SY5Y cells). After cells had adhered generally overnight,
but no sooner than 4 h later, the medium was removed and replaced
with 250 μL per well of complete medium supplemented with
∼350000 cpm of 86Rb+ (NEN; counted at 40% efficiency using
Cerenkov counting and the Packard TriCarb 1900 Liquid Scintillation
Analyzer). After at least 4 h and typically overnight, 86Rb+ efflux was
measured using the “flip-plate” technique. Briefly, after aspiration of
the bulk of 86Rb+ loading medium from each well of the “cell plate,”
each well containing cells was rinsed with 2 mL of fresh 86Rb+ efflux
buffer (130 mM NaCl, 5.4 mM KCl, 2 mM CaCl2, 5 mM glucose, and
50 mM HEPES; pH 7.4) to remove extracellular 86Rb+. Following
removal of residual rinse buffer by aspiration, the flip-plate technique
was used again to simultaneously introduce 1.5 mL of fresh efflux
buffer containing drugs of choice at indicated final concentrations from
a 24-well “efflux/drug plate” into the wells of the cell plate. After a 9.5
min incubation, the solution was “flipped” back into the efflux/drug
plate, and any remaining buffer in the cell plate was removed by
aspiration. Ten minutes after the initiation of the first drug treatment,
a second efflux/drug plate was used to reintroduce the same
concentrations of drugs of choice with the addition of an ∼EC90
concentration of the full agonist carbamylcholine for 5 min (∼EC90
concentrations were 200 μM for SH-EP1-hα4β2 cells, 2 mM for
SHSY5Y cells, and 464 mM for TE671/RD cells). The second drug
treatment was then flipped back into its drug plate, and the remaining
cells in the cell plate were lysed and suspended by addition of 1.5 mL
of 0.1 M NaOH with 0.1% sodium dodecyl sulfate to each well.
Suspensions in each well were then subjected to Cerenkov counting
(Wallac Micobeta Trilux 1450; 25% efficiency) after placement of
inserts (Wallac 1450-109) into each well to minimize cross-talk
between wells.
For quality control and normalization purposes, the sum of 86Rb+ in
cell plates and efflux/drug plates was defined to confirm material
balance (i.e., that the sum of 86Rb+ released into the efflux/drug plates
and 86Rb+ remaining in the cell plate were the same for each well).
Similarly, the sum of 86Rb+ in cell plates and efflux/drug plates also
determined the efficiency of 86Rb+ loading (the percentage of applied
86Rb+ actually loaded into cells). Furthermore, the sum of 86Rb+ in cell
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plates and the second efflux/drug plates defined the amount of
intracellular 86Rb+ available at the start of the second, 5 min assay and
were used to normalize nAChR function assessed.
For each experiment, in one set of control samples, total 86Rb+
efflux was assessed in the presence of a fully efficacious concentration
of carbamylcholine alone (1 mM for SH-EP1-hα4β2 and TE671/RD
cells, or 3 mM for SH-SY5Y cells). Nonspecific 86Rb+ efflux in another
set of control samples was measured either in the presence of the fully
efficacious concentration of carbamylcholine plus 100 μM mecamyl-
amine, which gave full block of agonist-induced and spontaneous
nAChR-mediated ion flux, or in the presence of efflux buffer alone.
Both determinations of nonspecific efflux were equivalent. Specific
efflux was then taken as the difference in control samples between total
and nonspecific 86Rb+-efflux. The same approaches were used to define
total, nonspecific, and specific ion flux responses in samples subjected
to the second, 5 min, exposure to test drug with or without
carbamylcholine at its ∼EC90 concentration.
Intrinsic agonist activity of test drugs was ascertained during the first
9.5 min of the initial 10 min exposure period using samples containing
test drug only at different concentrations and was normalized, after
subtraction of nonspecific efflux, to specific efflux in carbamylcholin
control samples. Specific 86Rb+ efflux elicited by test drug as a
percentage of specific efflux in carbamylcholine controls was the same
in these samples whether measured in absolute terms or as a
percentage of loaded 86Rb+. Even in samples previously giving an efflux
response during the initial 10 min exposure to a partial or full agonist,
residual intracellular 86Rb+ was adequate to allow assessment of
nAChR function in the secondary, 5 min assay. However, care was
needed to ensure that data were normalized to the amount of
intracellular 86Rb+ available at the time of the assay, as absolute levels
of total, nonspecific, or specific efflux varied in cells partially depleted
of intracellular 86Rb+ due to action of any agonist present during the
10 min drug exposure period. That is, calculations of specific efflux as a
percentage of loaded 86Rb+ typically were corrected for any variation in
the electrochemical gradient of 86Rb+ created by intracellular ion
depletion after the first (agonism/pretreatment) drug treatment.
Ion flux assays (n ≥ 3 separate studies for each drug and cell line
combination) were fit to the Hill equation, F = Fmax/(1 + (X/EC50)
n),
where F is the percentage of control, Fmax, for EC50 (n > 0 for agonists)
or IC50 (n < 0 for antagonists) values using Prism 4 (GraphPad, San
Diego, USA). Most ion flux data were fit allowing maximum and
minimum ion flux values to be determined by curve fitting but in some
cases, where antagonists or agonists had weak functional potency,
minimum ion flux was set at 0% of control or maximum ion flux was
set at 100% of control, respectively.
■ GENERAL PROCEDURES FOR BEHAVIORAL
STUDIES
Animals. BALB/cJ male mice (8−10 weeks old at testing)
were obtained from Jackson Laboratory (Bar Harbor, ME,
USA). Mice were housed four to a cage in a colony room
maintained at 22 ± 2 °C on a 12 h light−dark cycle. All animal
experiments were conducted in accordance with the NIH
Guide for the Care and Use of Laboratory Animals and the
PsychoGenics Animal Care and Use Committee.
Drugs. Compounds 43 were synthesized as described above,
and sertraline was purchased from Toronto Research
Chemicals (Ontario, Canada). All compounds were dissolved
in injectable water and administered by intraperitoneal (IP)
injection or oral gavage (PO) in a volume of 10 mL/kg.
Mouse Forced Swim Test. Procedures were based on
those previously described.25 Mice were individually placed into
clear glass cylinders (15 cm tall ×10 cm wide, 1 L beakers)
containing 23 ± 1 °C water 12 cm deep (approximately 800
mL). Mice were administered vehicle, the SSRI sertraline (10
or 20 mg/kg) as a positive control, or compound 43 (1 or 5
mg/kg). Thirty minutes following IP or PO administration,
mice were placed in the water, and the time the animal spent
immobile was recorded over a 6 min trial. Immobility was
defined as the postural position of floating in the water.
Statistical Analysis. Data were analyzed with analysis of
variance (ANOVA) with treatment group (vehicle, sertraline, or
compound 43 (1 and 5 mg/kg)) as the between group variable
and total time immobile (seconds over the 6 min trial) as the
dependent variable. Significant main effects were followed up
with the post hoc Fisher’s test.
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